Drug-induced QT interval prolongation and major adverse cardiac events: Meta-analysis of randomized controlled trials
| dc.contributor.author | Garcia, M | |
| dc.contributor.author | Tsang, J | |
| dc.contributor.author | Lohit, S | |
| dc.contributor.author | Deng, F | |
| dc.contributor.author | Chang, O | |
| dc.contributor.author | Cairns, K | |
| dc.contributor.author | Rehman, N | |
| dc.contributor.author | Hijazi, W | |
| dc.contributor.author | Mbuagbaw, L | |
| dc.contributor.author | Holbrook, AM | |
| dc.contributor.department | Medicine | en_US |
| dc.date.accessioned | 2023-10-17T14:05:35Z | |
| dc.date.available | 2023-10-17T14:05:35Z | |
| dc.date.issued | 2023-10 | |
| dc.description.abstract | Background: QT-prolonging medications (QTPMeds) have become a major source of clinical concern regarding medication-related major adverse cardiac events (MACE); MACE events are rare and it is not clear if all QTPMeds create harm, or in which circumstances. Objectives: Systematically review the study data on the association between QTPMedsand MACE; here we report on a subset of randomized trials. Discussion: Most trials are not statistically powered to detect MACE | en_US |
| dc.identifier.uri | http://hdl.handle.net/11375/29078 | |
| dc.language.iso | en | en_US |
| dc.subject | QT-prolonging medications | en_US |
| dc.subject | medication-related major adverse cardiac events | en_US |
| dc.subject | systematic review | en_US |
| dc.title | Drug-induced QT interval prolongation and major adverse cardiac events: Meta-analysis of randomized controlled trials | en_US |
| dc.type | Poster | en_US |